Therefore, these results suggest that good control of lipid metabolism by the drugs for dyslipidaemia may improve systemic immune activity and induce suppression of recurrence in postmenopausal HR-positive/HER2-negative breast cancer patients. This evidence concerns the gene ERBB2 and inherited lipid metabolism disorder.